Once-Weekly Dulaglutide Benefit in REWIND, Longest CVOT to Date Once-Weekly Dulaglutide Benefit in REWIND, Longest CVOT to Date

Full results of REWIND show dulaglutide significantly reduces CV events in patients with type 2 diabetes who primarily have CVD risk factors, rather than CVD itself. The major effect seems to be on stroke.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news